Sarah Cannon Research Institute

OncoGenex’s Spruce trial open for enrollment

Tuesday, August 6, 2013 10:30 AM

OncoGenex Pharmaceuticals has initiated the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled phase II trial evaluating OGX-427, a heat shock protein 27 (Hsp27) inhibitor, in patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

More... »

Morphotek announces initiation of phase I study for MORAb-066

Wednesday, July 3, 2013 02:16 PM

Biopharmaceutical Morphotek, a subsidiary of Eisai, has announced that the Sarah Cannon Research Institute in Nashville, Tenn., has opened enrollment in a phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies. The open-label, phase I study will assess the safety, tolerability and pharmacokinetics of MORAb-066 administered with weekly intravenous infusions.

More... »

Sarah Cannon, AstraZeneca partner for oncology

Tuesday, July 2, 2013 12:53 PM

Sarah Cannon Research Institute (SCRI) and AstraZeneca will collaborate to develop new AstraZeneca oncology compounds. The companies will work on molecular profiling to classify tissue based on genetic profiles for the purpose of treating cancers and predicting response to therapy.

More... »

Northwest Bio collaborates with U.K. cancer institutions for DCVaxR-Direct trial

Wednesday, November 7, 2012 11:51 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotechnology company developing DCVax personalized immune therapies for cancer, has initiated a collaboration with U.K.-based cancer institutions Sarah Cannon Research U.K. and Leaders in Oncology Care (LOC) on a phase I/II trial with DCVax-Direct for metastatic colon cancer. 

More... »

Marshall Edwards initiates phase I ME-143 trial

Friday, September 9, 2011 12:48 PM

Marshall Edwards, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, has initiated a phase I clinical trial of its lead drug candidate ME-143 in patients with refractory solid tumors. The trial is being conducted in collaboration with the Sarah Cannon Research Institute in Nashville, Tennessee, following the approval of an Investigational New Drug (IND) application by the FDA last month.

More... »

Sarah Cannon Research Institute names new CFO, CIO

Tuesday, March 22, 2011 12:02 PM

Sarah Cannon Research Institute (SCRI), based in Nashville, Tenn., has named Ajay Gupta chief financial officer and Andy Corts chief information officer.

More... »

Sarah Cannon Names New CFO

Friday, March 19, 2010 07:05 AM

Strategic research organization Sarah Cannon Research Institute (SCRI) appointed Dean Ferrigno as chief financial officer (CFO), replacing Phil Cestaro, who is now president, SCRI Services. SCRI Services specializes in clinical trial administration with a focus on oncology drug development programs. Cestaro, who joined the company in 2006, will continue to be SCRI’s chief information officer in addition to the new position.

More... »

University of Oklahoma, Sarah Cannon Partner on Early-Stage Cancer Research

Monday, March 8, 2010 06:43 AM

The University of Oklahoma’s OU Cancer Institute (OUCI) is partnering with strategic research organization Sarah Cannon Research Institute (SCRI) to expand the school’s early-phase oncology clinical trials program.

More... »